Drew Ranieri
Stock Analyst at Morgan Stanley
(1.21)
# 3,587
Out of 4,944 analysts
167
Total ratings
44.44%
Success rate
-12.69%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Maintains: Overweight | $75 → $68 | $62.12 | +9.47% | 13 | Jul 15, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.91 | +22.20% | 4 | Mar 5, 2025 | |
| ATEC Alphatec Holdings | Assumes: Equal-Weight | $9.5 → $10 | $15.90 | -37.11% | 10 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $375.77 | +18.42% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $15.57 | +22.03% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $14.10 | +91.49% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $6.84 | +17.04% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $22.05 | -0.23% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $8.95 | -10.61% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $12.82 | +543.53% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $21.32 | +78.28% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $52.43 | +83.12% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.04 | +135.51% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $194.92 | +51.34% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $121.42 | +130.60% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $7.33 | -31.79% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $24.08 | +190.70% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $477.77 | -37.21% | 6 | Apr 25, 2022 |
Globus Medical
Jul 15, 2025
Maintains: Overweight
Price Target: $75 → $68
Current: $62.12
Upside: +9.47%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.91
Upside: +22.20%
Alphatec Holdings
Dec 2, 2024
Assumes: Equal-Weight
Price Target: $9.5 → $10
Current: $15.90
Upside: -37.11%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $375.77
Upside: +18.42%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $15.57
Upside: +22.03%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $14.10
Upside: +91.49%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $6.84
Upside: +17.04%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $22.05
Upside: -0.23%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $8.95
Upside: -10.61%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $12.82
Upside: +543.53%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $21.32
Upside: +78.28%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $52.43
Upside: +83.12%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.04
Upside: +135.51%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $194.92
Upside: +51.34%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $121.42
Upside: +130.60%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $7.33
Upside: -31.79%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $24.08
Upside: +190.70%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $477.77
Upside: -37.21%